161 related articles for article (PubMed ID: 23915185)
21. A pilot study of salivary N-glycome in HBV-induced chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
Qin Y; Zhong Y; Ma T; Zhang J; Yang G; Guan F; Li Z; Li B
Glycoconj J; 2017 Aug; 34(4):523-535. PubMed ID: 28389847
[TBL] [Abstract][Full Text] [Related]
22. Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients.
Mustafa MG; Petersen JR; Ju H; Cicalese L; Snyder N; Haidacher SJ; Denner L; Elferink C
Mol Cell Proteomics; 2013 Dec; 12(12):3640-52. PubMed ID: 24008390
[TBL] [Abstract][Full Text] [Related]
23. Serum peptide pattern that differentially diagnoses hepatitis B virus-related hepatocellular carcinoma from liver cirrhosis.
Wang N; Cao Y; Song W; He K; Li T; Wang J; Xu B; Si HY; Hu CJ; Li AL
J Gastroenterol Hepatol; 2014; 29(7):1544-50. PubMed ID: 24612022
[TBL] [Abstract][Full Text] [Related]
24. Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy.
Wu FX; Wang Q; Zhang ZM; Huang S; Yuan WP; Liu JY; Ban KC; Zhao YN
Cancer Lett; 2009 Jul; 279(2):163-70. PubMed ID: 19268439
[TBL] [Abstract][Full Text] [Related]
25. MALDI-TOF-MS analysis in low molecular weight serum peptidome biomarkers for NSCLC.
Song Y; Xu X; Wang N; Zhang T; Hu C
J Clin Lab Anal; 2022 Apr; 36(4):e24254. PubMed ID: 35212031
[TBL] [Abstract][Full Text] [Related]
26. Serum profiling based on fucosylated glycoproteins for differentiating between chronic hepatitis B and hepatocellular carcinoma.
Liao J; Zhang R; Qian H; Cao L; Zhang Y; Xu W; Li J; Wu M; Yin Z
Biochem Biophys Res Commun; 2012 Apr; 420(2):308-14. PubMed ID: 22425980
[TBL] [Abstract][Full Text] [Related]
27. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases.
Paradis V; Degos F; Dargère D; Pham N; Belghiti J; Degott C; Janeau JL; Bezeaud A; Delforge D; Cubizolles M; Laurendeau I; Bedossa P
Hepatology; 2005 Jan; 41(1):40-7. PubMed ID: 15690480
[TBL] [Abstract][Full Text] [Related]
28. Screening serum hepatocellular carcinoma-associated proteins by SELDI-based protein spectrum analysis.
Cui JF; Liu YK; Zhou HJ; Kang XN; Huang C; He YF; Tang ZY; Uemura T
World J Gastroenterol; 2008 Feb; 14(8):1257-62. PubMed ID: 18300354
[TBL] [Abstract][Full Text] [Related]
29. Proteomic Profiling of Invasive Ductal Carcinoma (IDC) using Magnetic Beads-based Serum Fractionation and MALDI-TOF MS.
Yang J; Zhu J; He K; Zhao LY; Liu LY; Song TS; Huang C
J Clin Lab Anal; 2015 Jul; 29(4):321-7. PubMed ID: 25130542
[TBL] [Abstract][Full Text] [Related]
30. Detection of hepatocellular carcinoma using glycomic analysis.
Goldman R; Ressom HW; Varghese RS; Goldman L; Bascug G; Loffredo CA; Abdel-Hamid M; Gouda I; Ezzat S; Kyselova Z; Mechref Y; Novotny MV
Clin Cancer Res; 2009 Mar; 15(5):1808-13. PubMed ID: 19223512
[TBL] [Abstract][Full Text] [Related]
31. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples.
Göbel T; Vorderwülbecke S; Hauck K; Fey H; Häussinger D; Erhardt A
World J Gastroenterol; 2006 Dec; 12(47):7604-12. PubMed ID: 17171788
[TBL] [Abstract][Full Text] [Related]
32. ITIH4: Effective Serum Marker, Early Warning and Diagnosis, Hepatocellular Carcinoma.
Li X; Li B; Li B; Guo T; Sun Z; Li X; Chen L; Chen W; Chen P; Mao Y; Zeng Y
Pathol Oncol Res; 2018 Jul; 24(3):663-670. PubMed ID: 28828637
[TBL] [Abstract][Full Text] [Related]
33. MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of hepatocellular carcinoma.
Liu C; Shen J; Pan C; Yang L; Mou S; Wang H; Liang Y
Am J Clin Pathol; 2010 Aug; 134(2):235-41. PubMed ID: 20660326
[TBL] [Abstract][Full Text] [Related]
34. Serum peptide profiling: identifying novel cancer biomarkers for early disease detection.
Martorella A; Robbins R
Acta Biomed; 2007; 78 Suppl 1():123-8. PubMed ID: 17465330
[TBL] [Abstract][Full Text] [Related]
35. Two classifiers based on serum peptide pattern for prediction of HBV-induced liver cirrhosis using MALDI-TOF MS.
Cao Y; He K; Cheng M; Si HY; Zhang HL; Song W; Li AL; Hu CJ; Wang N
Biomed Res Int; 2013; 2013():814876. PubMed ID: 23509784
[TBL] [Abstract][Full Text] [Related]
36. Peptides in low molecular weight fraction of serum associated with hepatocellular carcinoma.
An Y; Bekesova S; Edwards N; Goldman R
Dis Markers; 2010; 29(1):11-20. PubMed ID: 20826913
[TBL] [Abstract][Full Text] [Related]
37. Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: sample variability and data classification.
Camaggi CM; Zavatto E; Gramantieri L; Camaggi V; Strocchi E; Righini R; Merina L; Chieco P; Bolondi L
Clin Chem Lab Med; 2010 Sep; 48(9):1319-26. PubMed ID: 20509833
[TBL] [Abstract][Full Text] [Related]
38. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
[TBL] [Abstract][Full Text] [Related]
39. Analysis of MALDI-TOF mass spectrometry data for detection of glycan biomarkers.
Ressom HW; Varghese RS; Goldman L; Loffredo CA; Abdel-Hamid M; Kyselova Z; Mechref Y; Novotny M; Goldman R
Pac Symp Biocomput; 2008; ():216-27. PubMed ID: 18229688
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis.
Guo Y; Zhao J; Bi J; Wu Q; Wang X; Lai Q
J Hematol Oncol; 2012 Jul; 5():37. PubMed ID: 22760167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
